339 related articles for article (PubMed ID: 27179655)
1. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
[TBL] [Abstract][Full Text] [Related]
2. [Metabolic Outcomes of Primary Aldosteronism Patients Receiving Adrenalectomy or Spironolactone Treatments].
Xu C; Chen T; Mo D; Zhang T; Zhou F; Tian H; Ren Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1227-1232. PubMed ID: 38162054
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
4. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
Giacchetti G; Ronconi V; Turchi F; Agostinelli L; Mantero F; Rilli S; Boscaro M
J Hypertens; 2007 Jan; 25(1):177-86. PubMed ID: 17143190
[TBL] [Abstract][Full Text] [Related]
6. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.
Iwakura Y; Morimoto R; Kudo M; Ono Y; Takase K; Seiji K; Arai Y; Nakamura Y; Sasano H; Ito S; Satoh F
J Clin Endocrinol Metab; 2014 May; 99(5):1593-8. PubMed ID: 24285678
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism.
Watanabe D; Morimoto S; Morishima N; Ichihara A
Endocrine; 2024 Apr; 84(1):245-252. PubMed ID: 38087188
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
Nakano Y; Murakami M; Hara K; Fukuda T; Horino M; Takeuchi A; Niitsu Y; Shiba K; Tsujimoto K; Komiya C; Yokoyama M; Ikeda K; Yoshimoto T; Fujii Y; Yamada T
Clin Endocrinol (Oxf); 2023 Mar; 98(3):323-331. PubMed ID: 36367014
[TBL] [Abstract][Full Text] [Related]
9. Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy.
Adolf C; Köhler A; Franke A; Lang K; Riester A; Löw A; Heinrich DA; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Arlt W; Reincke M
J Clin Endocrinol Metab; 2018 Dec; 103(12):4543-4552. PubMed ID: 30113683
[TBL] [Abstract][Full Text] [Related]
10. Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma.
Giacchetti G; Ronconi V; Rilli S; Guerrieri M; Turchi F; Boscaro M
Eur J Endocrinol; 2009 Apr; 160(4):639-46. PubMed ID: 19131503
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
[TBL] [Abstract][Full Text] [Related]
12. Primary aldosteronism: renaissance of a syndrome.
Young WF
Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
[TBL] [Abstract][Full Text] [Related]
13. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment.
Velema M; Dekkers T; Hermus A; Timmers H; Lenders J; Groenewoud H; Schultze Kool L; Langenhuijsen J; Prejbisz A; van der Wilt GJ; Deinum J;
J Clin Endocrinol Metab; 2018 Jan; 103(1):16-24. PubMed ID: 29099925
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone.
Künzel HE; Apostolopoulou K; Pallauf A; Gerum S; Merkle K; Schulz S; Fischer E; Brand V; Bidlingmaier M; Endres S; Beuschlein F; Reincke M
J Psychiatr Res; 2012 Dec; 46(12):1650-4. PubMed ID: 23017810
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas.
Karagiannis A; Tziomalos K; Kakafika AI; Athyros VG; Harsoulis F; Mikhailidis DP
Endocr Relat Cancer; 2008 Sep; 15(3):693-700. PubMed ID: 18586836
[TBL] [Abstract][Full Text] [Related]
16. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy.
Fischer E; Hanslik G; Pallauf A; Degenhart C; Linsenmaier U; Beuschlein F; Bidlingmaier M; Mussack T; Ladurner R; Hallfeldt K; Quinkler M; Reincke M
J Clin Endocrinol Metab; 2012 Nov; 97(11):3965-73. PubMed ID: 22893716
[TBL] [Abstract][Full Text] [Related]
17. Prediction of successful outcome in patients with primary aldosteronism.
Moo TA; Zarnegar R; Duh QY
Curr Treat Options Oncol; 2007 Aug; 8(4):314-21. PubMed ID: 18058076
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of surgical and conservative treatment of patients with primary aldosteronism.
Horký K; Widimský J; Hradec E; Gregorová I; Hradec M
Exp Clin Endocrinol; 1987 Dec; 90(3):337-46. PubMed ID: 3450533
[TBL] [Abstract][Full Text] [Related]
19. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma.
; Wu VC; Chueh SC; Chang HW; Lin LY; Liu KL; Lin YH; Ho YL; Lin WC; Wang SM; Huang KH; Hung KY; Kao TW; Lin SL; Yen RF; Chen YM; Hsieh BS; Wu KD
Am J Kidney Dis; 2009 Oct; 54(4):665-73. PubMed ID: 19628318
[TBL] [Abstract][Full Text] [Related]
20. Does the treatment of primary hyperaldosteronism influence glucose tolerance?
Strauch B; Widimský J; Sindelka G; Skrha J
Physiol Res; 2003; 52(4):503-6. PubMed ID: 12899664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
